GlobalRPh Renal Dosing Masterv7.4
Renal Dosing Master: fast drug lookup
Product-specific reference

Tofersen intrathecal injection (QALSODY)

Read renal action and limits

Qalsody / tofersen

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)
Review first - source-specific qualification

Not studied is not no adjustment

No renal or dialysis regimen is established by these selected PK statements; the mirror is older than the primary label.

Before applying: Use current specialist guidance and the complete exact-product label.

Evidence for this qualification

Selected-source comparison; independent clinician adjudication pending.

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Rxlist source

QALSODY: older RX mirror, selected PK passage

Product / population
QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.
Renal measure
Renal PK studies absent in selected passage.
Source revision
04/2023
Retrieved
2026-11-07 (not the revision date)

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Confirm the exact product, indication, renal measure, kidney trend and dialysis modality.

Selected renal instructions and limits

The April 2023 mirror also states that renal-impairment pharmacokinetic studies were not performed. The primary label retrieved for this update is dated November 2025; agreement of this selected paragraph does not establish equivalence of the full labels.

Source revision: 04/2023 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/qalsody-drug/

Scope: Selected named renal sections summarized; not a complete monograph or independent clinician sign-off. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

QALSODY: renal pharmacokinetic evidence gap

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Confirm the exact product, indication, renal measure, kidney trend and dialysis modality.

QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.

Renal method: No renal dosing measure or validated renal adjustment in the selected PK passage.
Retrieved: 2026-11-07

GlobalRPh RX List

QALSODY: older RX mirror, selected PK passage

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Confirm the exact product, indication, renal measure, kidney trend and dialysis modality.

QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.

Renal method: Renal PK studies absent in selected passage.
Retrieved: 2026-11-07

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

An RX mirror and its underlying label are not independent clinical confirmations.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81356b45-1cb7-4eef-88ea-e44cc18b47c5

Exact product and population

QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.

RDM70-tofersen-qalsody-43754ac270 · Source section: Exact product label: sections 1 and 3Renal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

QALSODY: renal pharmacokinetic evidence gap

Open original reference

Open / share this exact local source

DailyMed / Biogen QALSODY label · QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.

Renal method: No renal dosing measure or validated renal adjustment in the selected PK passage.
Source date: 11/2025
Retrieved: 2026-11-07

Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Confirm the exact product, indication, renal measure, kidney trend and dialysis modality.

Selected named renal sections summarized; not a complete monograph or independent clinician sign-off.

Selected renal instructions and limits

Dedicated pharmacokinetic studies in renal impairment have not been conducted. The selected label does not establish a renal adjustment or dialysis regimen. This is insufficient evidence, not proof that no adjustment is needed. Do not repurpose the intrathecal product for another route.

RDM70-tofersen-qalsody-1603e854fa · Source locator: Sections 1, 2.1 and 12.3

Source identity and provenance
Source family
product_label
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81356b45-1cb7-4eef-88ea-e44cc18b47c5
Retrieved
2026-11-07
Renal-function method
No renal dosing measure or validated renal adjustment in the selected PK passage.
Source date/version
11/2025
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
1603e854fa74ce4bb4dd55aa43de0b2ef4bbdad0f99b6dd31151a26e9dcdab1b
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

QALSODY: older RX mirror, selected PK passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / label mirror · QALSODY tofersen injection, intrathecal use, adults with SOD1-associated amyotrophic lateral sclerosis. Specialist administration only.

Renal method: Renal PK studies absent in selected passage.
Source date: 04/2023
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.
Before using this finding

Confirm the exact product, indication, renal measure, kidney trend and dialysis modality.

Selected named renal sections summarized; not a complete monograph or independent clinician sign-off.

Selected renal instructions and limits

The April 2023 mirror also states that renal-impairment pharmacokinetic studies were not performed. The primary label retrieved for this update is dated November 2025; agreement of this selected paragraph does not establish equivalence of the full labels.

RDM70-tofersen-qalsody-e9118ef213 · Source locator: Clinical Pharmacology: patients with renal or hepatic impairment

Source identity and provenance
Source family
product_label
Source
https://globalrph.com/rx-list/qalsody-drug/
Retrieved
2026-11-07
Renal-function method
Renal PK studies absent in selected passage.
Source date/version
04/2023
Hash meaning
Locally authored summary text; not original source HTML, XML or PDF bytes
Local summary SHA-256
e9118ef213b91fbc8eb9a58267e28dc9b05c85f1dee2e42e6d1f430a27945efe

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=81356b45-1cb7-4eef-88ea-e44cc18b47c5
Source retrieval
2026-11-07. This is not the source publication or label revision date.
Original source type
multisource addition
Local text SHA-256
43754ac270b8a9a9a6ed1c3fefc147842192d6486b8466144937a220d0555b07
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report
Top